1 / 2

FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in BaselFILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland January 25, 2017. REUTERS/Arnd Wiegmann

By Jonathan Stempel and Deena Beasley

NEW YORK/LOS ANGELES (Reuters) – Swiss drugmaker Novartis AG sued Amgen Inc on Thursday, accusing the U.S. biotechnology company of trying to wrongfully back out of agreements to jointly develop and market the migraine prevention drug Aimovig and keep the profits for itself.

The complaint filed in the U.S. District Court in Manhattan comes as drugmakers move to build share in the large market for new treatments to prevent migraine headaches.

Aimovig, which won U.S. and European approvals last year, belongs to

Read More At Article Source | Article Attribution